cd8-guided il-2 fusion protein azd6750
Generic: CD8-guided IL-2 Fusion Protein AZD6750
cd8-guided il-2 fusion protein azd6750: 1 clinical trial tracked.
cd8-guided il-2 fusion protein azd6750 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about cd8-guided il-2 fusion protein azd6750, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (1)
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
Primary endpoint: Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)
Interventionalopen120 targetStarted 2025-07Completion 2029-1013 sites · Australia, Japan, South Korea, United StatesAstraZeneca